News
GNNSF
1.820
NaN%
--
Genscript Biotech’s Associate to Present New Data at Hematology Meeting
TipRanks · 3d ago
Weekly Report: what happened at GNNSF last week (1027-1031)?
Weekly Report · 4d ago
Weekly Report: what happened at GNNSF last week (1020-1024)?
Weekly Report · 10/27 10:29
Weekly Report: what happened at GNNSF last week (1013-1017)?
Weekly Report · 10/20 10:26
Genscript Biotech’s ProBio Receives Significant Sublicense Revenue Boost
Barchart · 10/15 04:50
Genscript Biotech Reports Strong CARVYKTI® Sales in Q3 2025
TipRanks · 10/14 12:38
Weekly Report: what happened at GNNSF last week (1006-1010)?
Weekly Report · 10/13 10:29
Weekly Report: what happened at GNNSF last week (0929-1003)?
Weekly Report · 10/06 10:25
Weekly Report: what happened at GNNSF last week (0922-0926)?
Weekly Report · 09/29 10:27
Weekly Report: what happened at GNNSF last week (0915-0919)?
Weekly Report · 09/22 10:27
Genscript Biotech Grants Share Awards to Boost Employee Engagement
TipRanks · 09/21 10:38
Weekly Report: what happened at GNNSF last week (0908-0912)?
Weekly Report · 09/15 10:06
Weekly Report: what happened at GNNSF last week (0901-0905)?
Weekly Report · 09/08 10:07
Weekly Report: what happened at GNNSF last week (0825-0829)?
Weekly Report · 09/01 10:05
Weekly Report: what happened at GNNSF last week (0818-0822)?
Weekly Report · 08/25 10:10
J.P. Morgan Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)
TipRanks · 08/21 12:16
Weekly Report: what happened at GNNSF last week (0811-0815)?
Weekly Report · 08/18 10:06
Genscript Biotech Reports Strong Revenue Growth Amid Strategic Investments
TipRanks · 08/18 03:52
Genscript Biotech Reports Strong Revenue and Profit Growth in H1 2025
TipRanks · 08/17 10:37
More
Webull provides a variety of real-time GNNSF stock news. You can receive the latest news about Genscript Biotec through multiple platforms. This information may help you make smarter investment decisions.
About GNNSF
Genscript Biotech Corp is an investment holding company principally engaged in the manufacture and sale of life science research products and services. The Company operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The Company mainly operates its businesses in the domestic and overseas markets.